Identifying at risk patients of Liver Cancer
HepLOGIC is a digital clinical decision-support system that uses the POLAR business intelligence tool to prompt risk-based screening and support the care of people living with chronic viral hepatitis and reduce the incidence of preventable liver cancer. This point-of-care prompt highlights patients who may be at risk of liver cancer due to unmanaged viral hepatitis and provides clinical support to ensure they receive appropriate testing and care.
We are looking for 6 general practices to help us test HepLOGIC in a 14-month pilot and feasibility study that will start in April 2023.
The benefits of involvement include a $5000 practice payment, direct access to specialist advice in the management of viral hepatitis and support for PIP QI continuous quality improvement activities. Your practice can be involved it if uses Best Practice or Medical Director (Clinical) software, has at least 1,800 RACGP active patients, and participates in the POLAR data sharing research program.
The study is being led by the Doherty Institute and Royal Melbourne Hospital in partnership with PHNs. Contact firstname.lastname@example.org visit the study website or see the study flyer for more information.